Clinical characteristics at sampling of the patients according to CHD2
| Parameter . | Category . | Unmutated (n = 432) . | Mutated (n = 24) . | P . |
|---|---|---|---|---|
| Gender | Male (%) | 260 (60) | 18 (75) | |
| Age (y), median (range) | 61 (18-93) | 64 (36-79) | ||
| A | 367 (86%) | 24 (100%) | ||
| Binet stage | B | 48 (11%) | 0 (0%) | |
| C | 11 (3%) | 0 (0%) | ||
| 0 | 274 (64%) | 19 (79%) | ||
| Rai stage | I-II | 136 (32%) | 5 (21%) | |
| III-IV | 15 (4%) | 0 (0%) | ||
| Lymphocytes (×109/L), median (range) | 11.1 (1.1-203) | 13.2 (5.9-80) | ||
| Hemoglobin (g/L), median (range) | 141 (45-177) | 144 (117-175) | ||
| Platelets (×109/L), median (range) | 201 (7-791) | 206 (101-301) | ||
| β2 microglobulin | UNV | 92 (21%) | 3 (12%) | |
| LDH | UNV | 32 (7%) | 2 (8%) | |
| IGHV | Mutated | 264 (62%) | 18 (75%) | |
| CD38 | <30% | 327 (76%) | 21 (88%) | |
| ZAP-70 | <20% | 323 (75%) | 20 (83%) | |
| CD49d | <40% | 334 (78%) | 22 (96%) | .038 |
| Genetics | Del(13q) | 215 (50%) | 8 (33%) | |
| Trisomy 12 | 63 (15%) | 5 (21%) | ||
| Del(11q) | 42 (10%) | 3 (12%) | ||
| Del(17p) | 15 (4%) | 2 (8%) | ||
| NOTCH1 | Mutated | 54 (13%) | 3 (13%) | |
| SF3B1 | Mutated | 40 (9%) | 0 (0%) | |
| MYD88 | Mutated | 17 (4%) | 1 (4%) | |
| TP53 | Mutated | 14 (3%) | 1 (4%) | |
| Treated | 184 (44%) | 11 (48%) | ||
| 5-y TTT (95% CI) | A and B | 53% (44%-62%) | 62% (28%-96%) | |
| 5-y OS (95% CI) | All | 79% (72%-86%) | 70% (46%-94%) |
| Parameter . | Category . | Unmutated (n = 432) . | Mutated (n = 24) . | P . |
|---|---|---|---|---|
| Gender | Male (%) | 260 (60) | 18 (75) | |
| Age (y), median (range) | 61 (18-93) | 64 (36-79) | ||
| A | 367 (86%) | 24 (100%) | ||
| Binet stage | B | 48 (11%) | 0 (0%) | |
| C | 11 (3%) | 0 (0%) | ||
| 0 | 274 (64%) | 19 (79%) | ||
| Rai stage | I-II | 136 (32%) | 5 (21%) | |
| III-IV | 15 (4%) | 0 (0%) | ||
| Lymphocytes (×109/L), median (range) | 11.1 (1.1-203) | 13.2 (5.9-80) | ||
| Hemoglobin (g/L), median (range) | 141 (45-177) | 144 (117-175) | ||
| Platelets (×109/L), median (range) | 201 (7-791) | 206 (101-301) | ||
| β2 microglobulin | UNV | 92 (21%) | 3 (12%) | |
| LDH | UNV | 32 (7%) | 2 (8%) | |
| IGHV | Mutated | 264 (62%) | 18 (75%) | |
| CD38 | <30% | 327 (76%) | 21 (88%) | |
| ZAP-70 | <20% | 323 (75%) | 20 (83%) | |
| CD49d | <40% | 334 (78%) | 22 (96%) | .038 |
| Genetics | Del(13q) | 215 (50%) | 8 (33%) | |
| Trisomy 12 | 63 (15%) | 5 (21%) | ||
| Del(11q) | 42 (10%) | 3 (12%) | ||
| Del(17p) | 15 (4%) | 2 (8%) | ||
| NOTCH1 | Mutated | 54 (13%) | 3 (13%) | |
| SF3B1 | Mutated | 40 (9%) | 0 (0%) | |
| MYD88 | Mutated | 17 (4%) | 1 (4%) | |
| TP53 | Mutated | 14 (3%) | 1 (4%) | |
| Treated | 184 (44%) | 11 (48%) | ||
| 5-y TTT (95% CI) | A and B | 53% (44%-62%) | 62% (28%-96%) | |
| 5-y OS (95% CI) | All | 79% (72%-86%) | 70% (46%-94%) |
LDH, lactate dehydrogenase; OS, overall survival; TTT, time to treatment; UNV, upper normal value; ZAP-70, zeta-chain-associated protein kinase 70kDa.